Chicago、ILにおける乳がんの臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、乳がんに関する58件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Affiliated Oncologists IL, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 他1件
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
- The University of Chicago, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
被験者募集中第1/2相
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
被験者募集中
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
被験者募集中第3相
- Rush University Medical Center ( Site 0079), Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Chicago
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- Northwestern University, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
被験者募集中健康なボランティア歓迎
- University of Chicago, Chicago
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
被験者募集中第1/2相
- University of Illinois Hospital & Health Sciences System, Chicago
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Northwestern Memorial Hospital, Chicago
- RUSH MD Anderson Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- University of Chicago, Chicago
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
被験者募集中第1/2相
- Northwestern University, Chicago
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
被験者募集中第2相
- Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago, Chicago
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- 他4件
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Northwestern University, Chicago
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
被験者募集中健康なボランティア歓迎
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
被験者募集中第2相
- University of Chicago Medical Center, Chicago
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
被験者募集中第2相
- Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
被験者募集中第2相
- University of Illinois, Chicago
ATEMPT 2.0: Adjuvant T-DM1 vs TH
被験者募集中第2相
- The University of Chicago Medical Center, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Northwestern University, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
被験者募集中第2/3相
- Local Institution - 0280, Chicago
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Northwestern University - Northwestern Memorial Hospital, Chicago
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
被験者募集中第2相
- Northwestern University, Chicago
- University of Illinois College of Medicine - Chicago, Chicago
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
被験者募集中第4相
- University of Illinois, Chicago
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
被験者募集中第2相
- Northwestern University, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Northwestern University, Chicago
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
被験者募集中第1相
- University of Chicago Comprehensive Cancer Center, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- University of Chicago, Chicago
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
被験者募集中第2相
- Northwestern University, Chicago
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
被験者募集中
- Robert H. Lurie Comprehensive Cancer Center, Chicago
- University of Illinois Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
被験者募集中第2相
- University of Chicago Medical Center, Chicago
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- Rush MD Anderson Cancer Center, Chicago
- 他2件
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
被験者募集中第1相
- Northwestern Memorial Hospital, Chicago
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
被験者募集中第2相
- University of Chicago, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
被験者募集中
- University of Illinois, Chicago
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
被験者募集中第2相
- University of Chicago Medical Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- The University of Chicago Comprehensive Cancer Center, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
被験者募集中第4相
- University of Chicago Medical Center, Chicago
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
被験者募集中観察研究
- Rush Cancer Center, Chicago
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
被験者募集中第2相
- University of Illinois, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
被験者募集中観察研究
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
被験者募集中第3相
- John H Stroger Jr Hospital of Cook County, Chicago
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
被験者募集中第1相
- University of Chicago Medical Center, Chicago
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
被験者募集中観察研究
- University of Illinois at Chicago, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
被験者募集中観察研究健康なボランティア歓迎
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
他の都市における乳がんの試験
- New York City, NY134件の研究
- Houston, TX126件の研究
- Boston, MA111件の研究
- Nashville, TN80件の研究
- Los Angeles, CA72件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Durham, NC63件の研究
- Queens, NY63件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
- Baltimore, MD47件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肥満症41件の研究
- 肺がん41件の研究
- 卵巣がん36件の研究
- 脳卒中34件の研究
- 大腸癌33件の研究
- 心不全31件の研究
- 過体重28件の研究
- 頭頸部扁平上皮癌26件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。